BIM
OREX

BlackRock Investment Management’s Orexigen Therapeutics, Inc. OREX Stock Holding History

BlackRock Investment Management’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-38,229
Closed -$215K – 4279
2016
Q1 		$215K Buy
38,229
+997
+3% +$12.9K ﹤0.01% 3146
2015
Q4 		$640K Buy
37,232
+67
+0.2% +$1.6K ﹤0.01% 2889
2015
Q3 		$784K Buy
37,165
+296
+0.8% +$10.1K ﹤0.01% 2781
2015
Q2 		$1.82M Buy
36,869
+1,108
+3% +$66.2K ﹤0.01% 2319
2015
Q1 		$2.8M Buy
35,761
+385
+1% +$23.9K ﹤0.01% 1795
2014
Q4 		$2.14M Sell
35,376
-497
-1% -$25K ﹤0.01% 1983
2014
Q3 		$1.53M Buy
35,873
+2,289
+7% +$123K ﹤0.01% 2205
2014
Q2 		$2.08M Buy
33,584
+2,863
+9% +$166K ﹤0.01% 2052
2014
Q1 		$2M Buy
30,721
+3,035
+11% +$205K ﹤0.01% 2049
2013
Q4 		$1.56M Buy
27,686
+788
+3% +$44.3K ﹤0.01% 2191
2013
Q3 		$1.65M Buy
26,898
+1,903
+8% +$129K ﹤0.01% 2092
2013
Q2 		$1.46M Buy
+24,995
New +$1.54M ﹤0.01% 2098

Other funds holding OREX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BlackRock Investment Management's OREX Position: Q2 2016 in Review

BlackRock Investment Management sold out of Orexigen Therapeutics, Inc. (OREX) in Q2 2016, closing a stake of 38,229 shares — an estimated $215K sold.

BlackRock Investment Management first reported a position in OREX in Q2 2013 and held it in 12 quarters. The position peaked at $2.8M in Q1 2015. 73 funds tracked by Wall St. Rank hold OREX as of Q2 2016.

  • BlackRock Investment Management reported no remaining Orexigen Therapeutics, Inc. position as of Q2 2016 after selling out during the quarter.
  • BlackRock Investment Management sold 38,229 Orexigen Therapeutics, Inc. shares in Q2 2016, an estimated $215K.
  • BlackRock Investment Management first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 12 quarters.
  • BlackRock Investment Management's Orexigen Therapeutics, Inc. position peaked at $2.8M in Q1 2015.
  • 73 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q2 2016.

Based on BlackRock Investment Management's 13F filing for Q2 2016, filed 10 Aug 2016.